These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34415673)

  • 21. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
    Sechaud R; Gu H; Rahmanzadeh G; Chiparus O; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):535-547. PubMed ID: 39110203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
    Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
    Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
    Choi H; Huang F; Flack M
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
    Long A; Yamamiya I; Valentine M; Machnes Z; Hangai N; Anderson B; Wacheck V; Gao L
    Clin Transl Sci; 2024 Sep; 17(9):e70012. PubMed ID: 39258521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
    Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
    Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.
    Offman E; Davidson M; Nilsson C
    J Clin Lipidol; 2017; 11(3):739-748. PubMed ID: 28506390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.
    Trivedi A; Malik FI; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):185-193. PubMed ID: 34145992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
    Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
    Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
    Haberer LJ; McSherry I; Cargill A; McCarthy L
    Eur J Clin Pharmacol; 2014 Jan; 70(1):37-45. PubMed ID: 24100471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects.
    Moon SJ; Jeon JY; Jang K; Yu KS; Lim Y; Kim MG
    Drug Des Devel Ther; 2019; 13():2533-2542. PubMed ID: 31440035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study.
    Otani N; Wakuda H; Imai H; Kuranari M; Ishii Y; Ito Y; Okubo A; Ogawa O; Takeda K; Ohyama T; Hasunuma T; Uemura N
    Clin Transl Sci; 2019 Sep; 12(5):513-518. PubMed ID: 31095880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
    Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects.
    Trivedi A; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Terminello B; Bhatia A; Dutta S; Lee E
    Clin Drug Investig; 2021 Jul; 41(7):639-645. PubMed ID: 34110614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.
    Hu M; Lee HK; To KK; Fok BS; Wo SK; Ho CS; Wong CK; Zuo Z; Chan TY; Chan JC; Tomlinson B
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1471-1478. PubMed ID: 27651239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.